Latest Asx Listing News

Lord Resources has completed a $814,000 placement by issuing 22 million shares, reinforcing its funding position as it advances exploration at the Ilgarari Copper Project in Western Australia.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Peak Rare Earths has officially been acquired by Shenghe Resources, with shareholders paid $0.443 per share and delisting from the ASX imminent. This marks a significant consolidation in the rare earths sector.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Tungsten Mining NL has successfully raised $9.5 million through a share placement to advance its Mt Mulgine gold-tungsten project, reinforcing its position in the global tungsten market.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.